PMC8245233_01
Vital signs from IVC clamp until 90 minutes following MB administration. IVC, inferior vena cava; PV, portal vein; PR, postreperfusion; MB, methylene blue.
CRIA2021-6610754.001.jpg
PMC8245233_01_CRIA2021-6610754.001.jpg
fig1
As seen in Figure 1, her hemodynamics improved and no longer required escalating doses of vasoactive medications.  Figure 2shows that though she remained on vasopressin (0.04 units/min) and norepinephrine (8 mcg/min) when transferred to the ICU, her clinical picture improved.
Vasoactive medication use during case #1.
CRIA2021-6610754.002.jpg
PMC8245233_01_CRIA2021-6610754.002.jpg
fig2
As seen in Figure 1, her hemodynamics improved and no longer required escalating doses of vasoactive medications.  Figure 2shows that though she remained on vasopressin (0.04 units/min) and norepinephrine (8 mcg/min) when transferred to the ICU, her clinical picture improved.
PMC8245233_02
Vital signs from IVC clamp until 90 minutes following MB administration.
CRIA2021-6610754.003.jpg
PMC8245233_02_CRIA2021-6610754.003.jpg
fig3
Figures 3 and 4 show the effects of MB on her blood pressure and we were able to rapidly wean down her vasopressor requirements.
Vasoactive medication use during case #2.
CRIA2021-6610754.004.jpg
PMC8245233_02_CRIA2021-6610754.004.jpg
fig4
Figures 3 and 4 show the effects of MB on her blood pressure and we were able to rapidly wean down her vasopressor requirements.
PMC8245233_03
Vital signs from IVC clamp until 90 minutes following MB administration.
CRIA2021-6610754.005.jpg
PMC8245233_03_CRIA2021-6610754.005.jpg
fig5
This improved his hemodynamics quickly as noted in Figure 5.  Figure 6shows that 22 minutes after administration of MB, the norepinephrine infusion was discontinued.
Vasoactive medication use during case #3.
CRIA2021-6610754.006.jpg
PMC8245233_03_CRIA2021-6610754.006.jpg
fig6
This improved his hemodynamics quickly as noted in Figure 5.  Figure 6shows that 22 minutes after administration of MB, the norepinephrine infusion was discontinued.